Olutasidenib + CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe Substrates
ApprovedRecruiting 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
AML (Acute Myeloid Leukemia)
Conditions
AML (Acute Myeloid Leukemia), Glioma, Cholangiocarcinoma, Solid Tumor Malignancies
Trial Timeline
Feb 23, 2026 → Jun 30, 2027
NCT ID
NCT07486713About Olutasidenib + CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe Substrates
Olutasidenib + CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe Substrates is a approved stage product being developed by Rigel Pharmaceuticals for AML (Acute Myeloid Leukemia). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07486713. Target conditions include AML (Acute Myeloid Leukemia), Glioma, Cholangiocarcinoma.
Hype Score Breakdown
Clinical
30
Activity
20
Company
2
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07486713 | Approved | Recruiting |
Competing Products
6 competing products in AML (Acute Myeloid Leukemia)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Gilteritinib + Venetoclax + Azacitidine (AZA) + Local standard of care (SOC) | Astellas Pharma | Phase 2/3 | 65 |
| ticagrelor 90 mg | AstraZeneca | Pre-clinical | 23 |
| Roflumilast + Placebo | AstraZeneca | Phase 2 | 52 |
| milatuzumab | Gilead Sciences | Phase 1 | 32 |
| Conditioning Regimen A + Conditioning Regimen B + Conditioning Regimen C + Conditioning Regimen D + Conditioning Regimen E + PTCy (50 mg/kg D3, D4) + PTCy (25 mg/kg D3, D4) + Post-transplant Tacrolimus + Post-transplant Mycophenolate mofetil + Post-transplant Abatacept + Post-transplant Ruxolitinib + Supportive Care: Growth Factors + Supportive Care: Seizure prophylaxis + Supportive Care: Prophylaxis against infections | Incyte | Phase 2 | 49 |
| p.DOM-WT1-37 DNA Vaccine and p.DOM-WT1-126 DNA Vaccine | Inovio Pharmaceuticals | Phase 2 | 44 |